Friday 16 October 2026
Export ALXO’s income statement to Excel — free account
ALX Oncology Holdings Inc.
ALXO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.06
0.06
+6.00%
Follow ALXO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
— | — | — | — | — | 154.45 | — | — | — |
P/S ratio |
— | — | — | — | — | 653.57 | 25.44 | 25.44 | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | 77.60 | (32.25) | — | — |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
— | — | — | — | — | (117.03) | (15.41) | (15.41) | — |
P/B ratio |
— | — | — | — | — | 3.71 | 0.00 | 0.00 | — |
Price to Tangible BV |
— | — | — | — | — | 3.71 | 0.00 | 0.00 | — |
EV/Sales |
— | — | — | — | — | 477.83 | 0.67 | 0.67 | — |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
— | — | — | — | — | (30.43) | (0.12) | (0.12) | — |
EV/FCF |
— | — | — | — | — | (30.40) | (0.12) | (0.12) | — |
Quick Ratio |
1.82 | 6.91 | 5.08 | 9.40 | 23.78 | 69.99 | 1.92 | 4.91 | — |
Current Ratio |
2.07 | 7.26 | 5.24 | 9.57 | 24.00 | 70.28 | 1.97 | 5.45 | — |
Net Debt/EBITDA |
0.34 | 0.81 | 0.99 | 2.00 | 4.32 | 10.09 | 0.19 | 0.62 | — |
Debt/Assets |
16.51% | 6.70% | 3.97% | 3.40% | 0.68% | 0.00% | 50.78% | 0.00% | 0.00% |
Debt/Equity |
0.38 | 0.09 | 0.05 | 0.04 | 0.01 | 0.00 | (0.08) | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.90 | 0.00 | — |
Operating CF/Net income |
0.83 | 0.90 | 0.81 | 0.72 | 0.82 | 0.75 | 0.61 | 0.76 | — |
Capex/Depreciation |
0.83 | 0.13 | 0.24 | 2.58 | (96.53) | (0.05) | (0.80) | (1.52) | — |
Interest Coverage |
(64.93) | (82.40) | (108.80) | (535.45) | (6,427.31) | (53.84) | (913.48) | — | — |
| (145.70%) | (88.91%) | (70.97%) | (39.42%) | (21.05%) | (28.36%) | 38.02% | 28.43% | — | |
| (98.34%) | (69.10%) | (58.58%) | (35.97%) | (20.45%) | (22.81%) | (435.95%) | 0.00% | — | |
ROIC |
0.00% | 0.00% | (640.53%) | (1,036.13%) | (2,661.67%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(371.50%) | (113.55%) | (102.92%) | (50.09%) | (23.67%) | (11.85%) | (409.34%) | (187.30%) | — |
Average Days of Receivables |
— | — | — | 0.00 | — | 0.00 | 40.79 | 164.58 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2,450.17% | 339.99% | 545.23% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,252.88% | 69.08% | 125.83% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 459.90% | 6.19% | 13.01% | — |
Graham Net Nets |
— | — | — | — | — | 0.27 | (0.91) | (0.91) | — |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | — | — | — | (8.13%) | (28.29%) | (28.29%) | — |
Free Cash Flow Yield |
— | — | — | — | — | (2.40%) | (22.26%) | (22.26%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 1.56 | 0.75 | — |
Operating CF per Share |
(1.57) | (2.34) | (3.03) | (2.19) | (1.69) | (2.07) | (4.63) | (4.79) | — |
Capex per Share |
0.00 | (0.01) | (0.03) | (0.04) | (0.12) | 0.00 | (0.11) | (0.24) | — |
Free Cash Flow per Share |
(1.57) | (2.35) | (3.06) | (2.23) | (1.81) | (2.07) | (4.75) | (5.03) | — |
Cash per Share |
0.83 | 2.45 | 4.25 | 6.54 | 9.02 | 23.49 | 2.93 | 3.00 | — |
Shareholders Equity per Share |
0.48 | 2.18 | 4.41 | 6.47 | 9.01 | 23.25 | (22.96) | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.48 | 2.18 | 4.41 | 6.47 | 9.01 | 23.25 | (22.96) | 0.00 | — |
Free Cash Flow |
(84.35) | (122.36) | (131.64) | (90.65) | (73.02) | (38.32) | (14.60) | (13.84) | — |
Working Capital |
26.17 | 115.85 | 152.66 | 242.64 | 351.72 | 429.79 | 4.83 | 8.34 | — |
Capital Expenditures |
(0.21) | (0.45) | (1.27) | (1.43) | (4.92) | (0.03) | (0.35) | (0.65) | — |
Net Current Asset Value |
17.66 | 100.20 | 135.82 | 227.94 | 349.89 | 429.78 | (71.51) | 10.21 | — |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.07 | 0.32 | — |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
(0.21) | (1.21) | (1.50) | (0.14) | 0.06 | 11.98 | 0.51 | 0.45 | — |
Cash ROIC |
(104.76%) | (48.69%) | (34.45%) | (16.78%) | (10.01%) | (4.43%) | 25.98% | (167.55%) | — |
Accounts Receivable Turnover |
— | — | — | 0.00 | — | 0.00 | 6.53 | 2.82 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.57 | 1.96 | 0.85 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36 | 313.77 | 135.32 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 0.77 | — | — | 0.73 | 0.73 | — |
Average Payables |
4.71 | 6.54 | 8.33 | 5.92 | 1.88 | 1.88 | 2.22 | 2.22 | — |
Average Assets |
103.41 | 195.16 | 274.52 | 343.34 | 408.12 | 223.37 | 5.34 | 0.00 | — |
Average Common Equity |
69.80 | 151.67 | 226.59 | 313.26 | 396.45 | 179.60 | (61.21) | (61.21) | — |
Columns are period end dates